Skip to main content

Table 1 Patient demographics and baseline characteristics (full analysis set)

From: Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

  Placebo Empagliflozin 10 mg Empagliflozin 25 mg
N 21 20 19
Male 17 (81.0) 14 (70.0) 16 (84.2)
Age (years) 60.7 (10.8) 64.8 (5.9) 62.6 (7.8)
Time since diagnosis of type 2 diabetes    
 ≤5 years 9 (42.9) 4 (20.0) 5 (26.3)
 >5 to 10 years 9 (42.9) 8 (40.0) 7 (36.8)
 >10 years 3 (14.3) 8 (40.0) 7 (36.8)
Number of anti-diabetes medications    
 0 18 (85.7) 16 (80.0) 17 (89.5)
 1 3 (14.3) 4 (20.0) 2 (10.5)
Body weight (kg) 67.7 (10.0) 63.5 (10.6) 65.9 (12.1)
Body mass index (kg/m2) 24.9 (2.8) 24.1 (3.7) 24.0 (3.2)
HbA1c (%) 8.00 (0.82) 7.99 (0.83) 7.73 (0.75)
Fasting plasma glucose (mg/dl)* 154.5 (19.8) 151.0 (21.6) 151.9 (23.3)
AUC1-4 h for postprandial glucose (mg · h/dl) 682.8 (91.2) 680.4 (92.2) 658.1 (116.2)
24-hour mean glucose (mg/dl) 184.1 (30.5) 181.3 (25.9) 178.4 (33.4)
Mean amplitude of glucose excursions, MAGE (mg/dl) 91.4 (26.4) 94.1 (18.5) 89.1 (29.7)
Estimated glomerular filtration rate (ml/min/1.73 m2) (Japanese estimation equation [27]) 82.6 (12.8) 76.5 (11.1) 80.7 (9.3)
Systolic blood pressure (mmHg)* 119.8 (11.5) 119.1 (15.9) 124.0 (11.6)
Diastolic blood pressure (mmHg)* 71.8 (7.7) 70.7 (10.7) 74.7 (8.0)
  1. Data are n (%) or mean (standard deviation). *Baseline for these parameters is day 1.